SC 13G: Embecta Corp.

Ticker: EMBC · Form: SC 13G · Filed: Oct 25, 2024 · CIK: 1872789

Embecta CORP. SC 13G Filing Summary
FieldDetail
CompanyEmbecta CORP. (EMBC)
Form TypeSC 13G
Filed DateOct 25, 2024
Risk Levellow
Pages7
Reading Time8 min
Sentimentneutral

Sentiment: neutral

Topics: sc-13g

AI Summary

SC 13G filing by Embecta Corp..

Risk Assessment

Risk Level: low

FAQ

What type of filing is this?

This is a SC 13G filing submitted by Embecta CORP. (ticker: EMBC) to the SEC on Oct 25, 2024.

What is the risk level of this SC 13G filing?

This filing has been assessed as low risk.

How long is this filing?

Embecta CORP.'s SC 13G filing is 7 pages with approximately 2,022 words. Estimated reading time is 8 minutes.

Where can I view the full SC 13G filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 2,022 words · 8 min read · ~7 pages · Grade level 6.8 · Accepted 2024-10-25 17:45:30

Filing Documents

(a)

Item 1(a). Name of Issuer: Embecta Corp.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 300 Kimball Drive, Suite 300 Parsippany, NJ 07054

(a)

Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

(b)

Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

(c)

Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn – United States citizen

(d)

Item 2(d). Title of Class of Securities: Common Stock

(e)

Item 2(e). CUSIP Number: 29082K105 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; CUSIP No. 29082K105 13G Page 7 of 9 (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________________________ Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned**: Deerfield Mgmt, L.P. - 3,075,335 shares Deerfield Management Company, L.P. - 3,075,335 shares Deerfield Partners, L.P. - 3,075,335 shares James E. Flynn – 3,075,335 shares (b) Percent of class**: Deerfield Mgmt, L.P. – 5.33% Deerfield Management Company, L.P. – 5.33% Deerfield Partners, L.P. – 5.33% James E. Flynn – 5.33% (c) Number of shares as to which such person has**: (i) Sole power to vote or to direct the vote: All Reporting Persons - 0 (ii)

Statement

Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn. Exhibit A Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Foghorn Therapeutics Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD PARTNERS, L.P. By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact JAMES E. FLYNN /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact Exhibit B Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

View Full Filing

View this SC 13G filing on SEC EDGAR

View on Read The Filing